Dietary Reference Intakes based on chronic disease endpoints: outcomes from a case study workshop for omega 3's EPA and DHA.
Aging
/ physiology
Biomedical Research
Brain
/ growth & development
Canada
Cardiovascular Diseases
/ prevention & control
Child
Child Development
Chronic Disease
/ prevention & control
Diet
Docosahexaenoic Acids
/ administration & dosage
Eicosapentaenoic Acid
/ administration & dosage
Female
Humans
Immunity
Infant
Inflammation
/ prevention & control
Pregnancy
Pregnancy Complications
/ prevention & control
Premature Birth
/ prevention & control
Recommended Dietary Allowances
Risk Factors
acide docosahexaénoïque
acide eicosapentaénoïque
acides gras oméga-3
apports nutritionnels de référence
cardiovascular disease
chronic disease
dietary reference intakes
docosahexaenoic acid
eicosapentaenoic acid
health outcomes
maladie cardiovasculaire
maladie chronique
naissance prématurée
omega-3 fatty acids
pre-term birth
état de santé
Journal
Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme
ISSN: 1715-5320
Titre abrégé: Appl Physiol Nutr Metab
Pays: Canada
ID NLM: 101264333
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
pubmed:
16
2
2021
medline:
5
11
2021
entrez:
15
2
2021
Statut:
ppublish
Résumé
Given the focus on developing Dietary Reference Intakes (DRIs) based on chronic disease risk reduction and recent research for omega-3 long chain PUFA since the last DRI review, the Canadian Nutrition Society convened a panel of stakeholders for a 1-day workshop in late 2019. Attendees discussed the new NASEM guidelines for establishing DRI values based on chronic disease risk endpoints and the strength of current evidence for EPA and DHA as it relates to the new guidelines.
Identifiants
pubmed: 33583256
doi: 10.1139/apnm-2020-0994
doi:
Substances chimiques
Docosahexaenoic Acids
25167-62-8
Eicosapentaenoic Acid
AAN7QOV9EA
Types de publication
Consensus Development Conference
Journal Article
Langues
eng
Sous-ensembles de citation
IM